Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

KKR Dark Aggregator sells 19.4m Darktrace shares in placing

(Sharecast News) - Jefferies said on Friday that KKR Dark Aggregator sold 19.4m shares in cybersecurity firm Darktrace in a placing. The shares were placed at 425p each, which is a discount of 7.8% to the closing share price on Thursday.

KKR Dark Aggregator is a technology growth fund advised by US private equity firm KKR.

Jefferies said the placing represents a full exit by the first technology growth fund (NGT I) advised by KKR and its affiliates that first invested in Darktrace in 2016.

The second technology growth fund (NGT II) advised by KKR did not participate in the placing and will continue to hold a stake of around 7.3%.

Jefferies and Berenberg acted as joint global co-ordinators and joint bookrunners on the placing.

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.